Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

iparomlimab/tuvonralimab (PSB205)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Qilu Pharma, Sound Biologics

Drug class:

PD1 inhibitor, CTLA4 inhibitor

Related drugs:

‹

pembrolizumab (726)

nivolumab (607)

sintilimab (115)

toripalimab-tpzi (88)

camrelizumab (85)

tislelizumab (84)

dostarlimab-gxly (42)

cemiplimab-rwlc (29)

zimberelimab (20)

pucotenlimab (12)

cadonilimab (10)

serplulimab (6)

retifanlimab-dlwr (6)

PF-06801591 (6)

JNJ-63723283 (5)

nivolumab/relatlimab (4)

geptanolimab (3)

CMAB 819 (nivolumab biosimilar) (0)

EBV-specific anti-PD1 TCR-T cells (0)

enlonstobart (0)

prolgolimab (0)

NY-ESO-1 TCR-T cell therapy (0)

prolgolimab/nurulimab (0)

PD-1 knockout engineered T cells (0)

PF-07209960 (0)

Undisclosed PD-1 inhibitor (0)

Undisclosed anti PD-1 mAb (0)

anti-PD-1 antibody (0)

ipilimumab (223)

tremelimumab (60)

ipilimumab biosimilar (CS1002) (2)

CTLA4 inhibitor (0)

IBI310 (ipilimumab biosimilar) (0)

PF-06753512 (0)

›

EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	PSB205 Sensitive: C3 – Early Trials PSB205 Sensitive : C3	PSB205 Sensitive: C3 – Early Trials PSB205 Sensitive : C3
EGFR wild-type	Lung Non-Small Cell Squamous Cancer	EGFR wild-type	Lung Non-Small Cell Squamous Cancer	PSB205 Sensitive: C3 – Early Trials PSB205 Sensitive : C3	PSB205 Sensitive: C3 – Early Trials PSB205 Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	bevacizumab + PSB205 Sensitive: C3 – Early Trials bevacizumab + PSB205 Sensitive : C3	bevacizumab + PSB205 Sensitive: C3 – Early Trials bevacizumab + PSB205 Sensitive : C3